The EHMT2 Knockout TE1 Polyclonal Cells represent a CRISPR/Cas9-edited cell population derived from the TE1 human esophageal squamous cell carcinoma line, featuring targeted disruption of the EHMT2 gene (G9a). This product offers a polyclonal knockout pool, which retains genetic heterogeneity and avoids clonal selection biases, providing a physiologically relevant loss-of-function model. It is designed for systematic investigation of EHMT2-mediated epigenetic silencing mechanisms and their functional impact on esophageal cancer cell behavior.
The host TE1 cell line originated from a well-differentiated human esophageal squamous cell carcinoma resected from a Japanese patient. These cells maintain characteristic epithelial morphology and are widely used as a model system for studying molecular pathways driving esophageal carcinogenesis, including epigenetic dysregulation, cell cycle abnormalities, and invasive properties. Their well-characterized nature makes them a suitable platform for evaluating the specific contribution of individual genes such as EHMT2 to the malignant phenotype.
EHMT2 encodes the histone methyltransferase G9a, responsible for mono- and di-methylation of histone H3 at lysine 9 (H3K9me1/H3K9me2), establishing repressive chromatin marks. Together with its obligate partner EHMT1 (GLP), EHMT2 interacts with co-repressors such as SNAI1, ZEB1, HDAC1, DNMT1, and MBD2 to enforce transcriptional silencing. Its expression is stimulated by E2F1, MYC, and PI3K/AKT signaling, and inhibited by TP53 and miR-217. The principal downstream effect is the epigenetic repression of tumor suppressor genes including CDKN1A (p21) and CDH1, leading to unchecked cell cycle progression and enhanced epithelial-mesenchymal transition, which collectively drive esophageal cancer aggressiveness.
In esophageal squamous cell carcinoma, aberrant overexpression of EHMT2 contributes to the silencing of critical tumor suppressors, fostering malignant proliferation and metastatic dissemination. The EHMT2 knockout TE1 polyclonal cells enable dissection of the causal role of EHMT2 in maintaining repressive H3K9me2 marks and suppressing gene expression programs. This model is particularly suited for examining the restoration of CDKN1A and CDH1 expression upon EHMT2 loss, assessing chromatin state changes at target loci, and determining the dependency of esophageal cancer cells on EHMT2-mediated epigenetic silencing for sustained growth and invasion.
These knockout cells support a wide range of applications, including mechanistic studies of epigenetic regulation in esophageal cancer, target validation for anti-EHMT2 therapeutics, and high-throughput screening of selective inhibitors such as UNC0638. Typical analytical workflows involve immunoblotting for global H3K9me2 changes, RT-qPCR quantification of CDKN1A and CDH1 transcript levels, ChIP-qPCR to measure H3K9me2 enrichment at specific promoter regions, and functional assays such as MTT/CCK-8 proliferation, transwell migration/invasion, and drug sensitivity testing. Researchers may also employ these cells in comparative genomic or proteomic profiling to uncover downstream mediators of EHMT2 signaling. For additional technical information or support, please contact Ascent Research.
